Sara Razi is Global Co-Chair of the Firm’s Antitrust and Trade Regulation Practice. She is a leading antitrust attorney, focusing on merger reviews, government antitrust investigations, antitrust litigation, and counseling on a variety of competition issues. Sara joined Simpson Thacher in 2013 from the FTC, where she served in senior roles for nearly a decade.
Sara regularly represents clients in antitrust investigations by the DOJ, FTC, and States and has secured successful outcomes in several complex and closely-watched mergers and high-profile antitrust litigations. Her extensive private-sector and government antitrust experience spans a multitude of industries including healthcare, pharmaceuticals, technology, supermarkets and other retailers, consumer products, financial services, media, and telecommunications.
Sara’s key matters include:
- Change Healthcare in its $13.8 billion acquisition by UnitedHealth Group, which won the Impact Case Award at Euromoney’s Benchmark Litigation Awards 2024, and was named “Merger Control Matter of the Year – Americas” at Global Competition Review’s GCR Awards 2023
- Mattress Firm in its $5 billion acquisition by Tempur Sealy International
- PPD in its $17.4 billion acquisition by Thermo Fisher Scientific
- HCA Healthcare in defeating the FTC’s first lawsuit over COPA
- AGCO in its formation of a $2 billion joint venture with Trimble
- Karuna Therapeutics in its $14 billion acquisition by Bristol-Myers Squibb Company
- Cohesity in its combination with Veritas’ data protection business, valued at $7 billion
Sara is recognized by The Legal 500 as a “Leading Lawyer” and by Chambers USA. Sources note that she is “a very seasoned and knowledgeable antitrust attorney” who “has the unique ability to give very practical advice about how regulators would react to matters,” with “extensive knowledge of agency strategy.” Sara is also ranked as one of the “Top 250 Women in Litigation” in the U.S. by Euromoney’s Benchmark Litigation, where she is highlighted for her “antitrust acumen” and “trial prowess” displayed during a recent merger litigation. In 2024, Sara was named “Antitrust Litigator of the Year” by Euromoney’s Benchmark Litigation, and in 2023, she was named a “MVP” in Competition/Antitrust by Law360; a Litigation “Trailblazer” by The National Law Journal; “Antitrust & Competition Lawyer of the Year” by Euromoney’s Women in Business Law Americas Awards; and among The Deal’s “Top Women in Dealmaking.” In 2025 she was again featured as one of Global Competition Review’s “Women in Antitrust” where she is separately described by GCR as one of the “best FTC merger advisers in the business.” Sara is an authority on antitrust issues and speaks frequently at conferences sponsored by the ABA, law schools, and private organizations. She also serves as Co-Chair of the Firm’s Pro Bono Committee and as a member of the DC Legal Aid board of trustees.
